1 Section of Urology, Department of Surgery, Centre Hospitalier de l'Université de Montréal , Montréal, Canada .
2 Division of Robotic Urology, Department of Surgery, Hôpital du Sacré Cœur de Montréal , Montreal, Canada .
J Endourol. 2018 Jun;32(6):509-515. doi: 10.1089/end.2017.0853. Epub 2018 Apr 25.
To study the functional outcome of patients undergoing transurethral enucleation and resection of the prostate (TUERP) vs patients undergoing holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction.
We retrospectively analyzed our prospectively collected database of two groups of patients. Twenty-four patients underwent TUERP (group 1), and 27 underwent HoLEP (group 2). Preoperative characteristics, intervention parameters, postoperative functional outcomes, uroflowmetry, and complications were collected.
Mean prostate size in groups 1 and 2 were 87.2 and 93.5 cc, respectively. The mean duration of surgery was 110 minutes in group 1 and 136 minutes in group 2. In group 1, prostate-specific antigen (PSA) dropped from 4.4 to 1.2 ng/cc after 12 months. International Prostate Symptom Score (IPSS) was 3.75 at 12 months with a preoperative value of 20.9. With respect to maximum urinary flow rate (Q), it increased to 21.8 mL/s from a preoperative value of 6.4 mL/s. In group 2, the PSA dropped from 7.6 to 1.3 ng/cc. IPSS dropped from 22.3 to 3.8, Q increased from 7.7 to 22.5 mL/s. Hemoglobin, complications, and all studied parameters were not statistically significant between both groups.
In this study, TUERP was safe and efficacious in benign prostatic hyperplasia patients with large glands. Modifications can be implemented on the standard transurethral resection of the prostate technique to treat patients with prostate sizes >70 cc.
研究经尿道前列腺剜除术（TUERP）与钬激光前列腺剜除术（HoLEP）治疗膀胱出口梗阻患者的功能结局。
我们回顾性分析了两组患者的前瞻性数据库。24 例患者接受 TUERP（组 1），27 例患者接受 HoLEP（组 2）。收集了术前特征、手术参数、术后功能结局、尿流率和并发症。
组 1 和组 2 的前列腺平均大小分别为 87.2 和 93.5cc。组 1 的手术时间平均为 110 分钟，组 2 为 136 分钟。在组 1 中，前列腺特异性抗原（PSA）从术前的 20.9 降至术后 12 个月的 4.4ng/cc。国际前列腺症状评分（IPSS）在术后 12 个月为 3.75，术前为 20.9。最大尿流率（Q）从术前的 6.4ml/s 增加到术后的 21.8ml/s。在组 2 中，PSA 从术前的 7.6ng/cc 降至术后 12 个月的 1.3ng/cc。IPSS 从术前的 22.3 降至术后的 3.8，Q 从术前的 7.7 增加到术后的 22.5ml/s。血红蛋白、并发症和所有研究参数在两组之间均无统计学差异。
在这项研究中，TUERP 治疗大腺体良性前列腺增生患者是安全有效的。可以对标准经尿道前列腺切除术进行改进，以治疗前列腺体积>70cc 的患者。
